China’s brain-computer interface trial cuts hydrocephalus diagnosis from days to 30 minutes

China has launched its first multi-center clinical trial using brain-computer interface (BCI) technology in neurocritical care. The research reported by Chinadaily focuses on conditions like hydrocephalus, which affects up to 50 percent of patients with cerebral hemorrhage and often results in prolonged diagnosis and high rates of misdiagnosis.

The trial, initiated in Tianjin, will provide new tools for diagnosing and managing severe neurological conditions. Researchers used domestically developed BCI devices with independently designed chips, and scientists have reduced the time required to diagnose hydrocephalus from two to three days to just 30 minutes, while improving accuracy.

It was by the Haihe Laboratory of Brain-Computer Interaction and Human-Machine Integration at Tianjin University, along with Tianjin Huanhu Hospital. Additionally, several renowned medical institutions from Beijing, Tianjin, Henan Province, and other regions played key roles in the project, as per the outlet.

What is BCI technology?

Brain-Computer Interface (BCI) technology is a system that enables direct communication between the brain and external devices by decoding the brain’s electrical signals into actionable commands. Using sensors or electrodes placed on or inside the brain, BCI devices capture neural activity, which is then interpreted by software or AI to control computers, robotic arms, wheelchairs, or communication tools.

The technology has wide-ranging applications, including restoring movement in paralyzed patients, helping those with speech disabilities, diagnosing neurological conditions, and, in the future, enhancing everyday activities like attention monitoring, sleep regulation, or device control. Essentially, BCI allows the brain to “talk” to machines, bypassing or assisting damaged neural pathways.

Tackling Hydrocephalus and Misdiagnosis

A key focus of the trial is hydrocephalus, a life-threatening condition caused by the buildup of cerebrospinal fluid in the brain. It is common among patients with cerebral hemorrhage, large craniectomies, traumatic brain injuries, or post-operative brain tumor complications. Current data suggest that 30–50 percent of cerebral hemorrhage patients and up to 40 percent of craniectomy patients develop the condition.

Hydrocephalus is often misdiagnosed as dementia or Parkinson’s disease, particularly in rural areas where the error rate reaches over 60 percent. Prolonged diagnostic timelines and limited treatment options further add to the clinical challenges.

Faster, more accurate BCI devices

At the same time, Tianjin University researchers unveiled a series of domestically developed BCI medical devices designed to address these gaps. Using self-developed acquisition and decoding chips, the team created wearable EEG devices capable of real-time monitoring of neurocritical indicators. These tools have reduced the diagnostic time for hydrocephalus from days to just 30 minutes while improving accuracy.

The trial builds on China’s decade-long BCI research progress, which began with the introduction of Shen Gong No.1, the world’s first artificial neurorehabilitation robot, in 2014.

Expanding clinical applications

Beyond hydrocephalus, the trial is expected to pave the way for broader BCI use in stroke rehabilitation, epilepsy management, and other critical neurological conditions. Tianjin Huanhu Hospital and the Haihe Laboratory, which are leading the effort, have already reported successful patient outcomes in earlier applications.